| Literature DB >> 35498604 |
Tahira Younis1,2, Faiza Jabeen2, Laila Jafri1,3, Azhar Rasul2, Maleeha Manzoor2, Mussarat Shaheen2,4, Ammara Riaz2.
Abstract
Secondary metabolites present in medicinal plants offer a golden opportunity to fight different ailments, such as cancer, infections, diabetes, neurodegenerative and cardiovascular diseases, etc. The traditional use of various parts of Fraxinus xanthoxyloides is known to serve as a cure for pneumonia, pain, jaundice, malaria, fracturing of bones, and internal wounds. The aim of this research was to validate the antioxidant and cardio-protective properties of F. xanthoxyloides leaves. The antioxidant potential was evaluated by employing different assays on the crude methanol extract, as well as its derived fractions. The extract/fraction that showed significant activity was further investigated for the presence of phytochemicals using high performance liquid chromatography-diode array detector (HPLC-DAD) analysis and also for cardio-protective potential. In the case of the antioxidant potential, the ethyl acetate fraction (FXE) was demonstrated to have the most potent total antioxidant (26.3 ± 2.4 AAE μg mg-1), hydroxyl ion scavenging (IC50 = 7.9 ± 0.9 μg mg-1), ferrous ion chelating (IC50 = 28.2 ± 2.7 μg mg-1) and nitric oxide scavenging (IC50 = 32.5 ± 2.9 μg mg-1) effects among all of the extract/fractions, whereas in the case of DPPH (IC50 = 17.5 ± 2.7 μg mg-1) and the reducing power assay (16.7 ± 2.8 GAE μg mg-1), promising antioxidant potential was shown by the n-butanol fraction. The presence of different concentrations of rutin, caffeic acid, catechin, and gallic acid was observed in the high performance liquid chromatography (HPLC) profile of FXE. Furthermore, in in vivo experimentation, the oral administration of FXE and silymarin significantly restored the CCl4-induced increase in the levels of creatine kinase, creatine kinase-MB, cholesterol and triacylglycerides when compared with the untreated group. FXE and silymarin treatment also restored the levels of the tissue antioxidant enzymes, for example glutathione-S-transferase, glutathione reductase, catalase, peroxidase and superoxide dismutase. Furthermore, significantly lower levels of reduced glutathione and enhanced levels of lipid peroxides, hydrogen peroxide, comet length and DNA damages were observed after CCl4 administration in the cardiac tissue of rats. FXE was able to restore these biochemical parameters, as well as the histological status of heart tissue. Based upon the present investigation, we concluded that F. xanthoxyloides leaves may have cardio-protective potential similar to silymarin against CCl4 induced injuries owing to its antioxidant constituents. This journal is © The Royal Society of Chemistry.Entities:
Year: 2020 PMID: 35498604 PMCID: PMC9050420 DOI: 10.1039/c9ra08729j
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
IC50 values of various antioxidant activities of FXM and its fractionsa
| Sample | DPPH assay | IC50 (μg ml−1) | TAC expressed as AAE μg per mg | Ferric ion reducing power expressed as GAE μg per mg | ||
|---|---|---|---|---|---|---|
| Hydroxyl ion scavenging | Ferrous ion chelation | Nitric oxide scavenging | ||||
| FXM | 47.3 ± 4.8c | 12.4 ± 2.1bc | 32.6 ± 3.4d | 34.5 ± 3.5c | 22.6 ± 2.1b | 14.6 ± 2.4b |
| FXH | 79.1 ± 5.2b | 19.5 ± 1.3a | 71.5 ± 5.1a | 60.2 ± 3.3a | 6.5 ± 2.9d | 5.5 ± 0.7c |
| FXC | >100a | 13.0 ± 2.0b | 45.5 ± 3.0c | 35.2 ± 2.8c | 11.7 ± 5.0c | 5.2 ± 1.1c |
| FXE | 20.2 ± 3.1d | 7.9 ± 0.9d | 28.2 ± 2.7e | 32.5 ± 2.9c | 26.3 ± 2.4a | 16.2 ± 3.1a |
| FXB | 17.5 ± 2.7e | 11.3 ± 1.1c | 33.1 ± 3.5d | 42.7 ± 2.1b | 12.5 ± 1.3c | 16.7 ± 2.8a |
| FXA | >100a | 17.3 ± 2.5a | 59.42 ± 3.4b | 63.3 ± 3.9a | 8.5 ± 1.6d | 6.2 ± 2.0c |
| Ascorbic acid | 8.8 ± 1.3d | 31.93 ± 3.5c | ||||
| Gallic acid | 7.03 ± 1.2d | 21.2 ± 2.9f | ||||
Data values are shown as mean ± SD (n = 3). Different superscripts (a–f) in each column indicate difference at the p < 0.01 level.
Fig. 1The impact of various FXM concentrations and the different fractions as indicated by several radical scavenging assays.
Fig. 2HPLC chromatograms of FXE: (A) rutin; (B) caffeic acid; and (C) gallic acid and catechin.
Impact of FXE on the biochemical parameters of serum in ratsa
| Treatment | Cholesterol (mg dl−1) | Triacylglycerides (mg dl−1) | CK (U l−1) | CK-MB (U l−1) |
|---|---|---|---|---|
| Control | 52.96 ± 1.65d | 43.60 ± 2.10cd | 82.00 ± 4.50c | 93.33 ± 4.63c |
| DMSO + olive oil | 52.40 ± 1.60d | 42.03 ± 2.71d | 87.00 ± 2.64c | 98.00 ± 5.00c |
| CCl4 + olive oil | 113.73 ± 3.91†a | 84.50 ± 2.33†a | 249 ± 37.17†a | 299.67 ± 18.17†a |
| CCl4 + silymarin | 79.30 ± 1.25†b | 63.40 ± 2.49†b | 96.00 ± 6.00bc | 117.67 ± 6.11bc |
| CCl4 + FXE (150) | 84.93 ± 3.38†b | 68.43 ± 2.23†b | 143.33 ± 11.06†b | 160.33 ± 14.57†b |
| CCl4 + FXE (300) | 63.50 ± 1.80†c | 50.60 ± 2.82#c | 86.67 ± 10.69c | 98.00 ± 7.00c |
| FXE (150) | 52.53 ± 1.10d | 43.30 ± 1.57cd | 85.67 ± 1.52c | 87.33 ± 6.50c |
| FXE (300) | 54.03 ± 2.47d | 42.73 ± 1.05d | 82.00 ± 3.00c | 90.67 ± 6.02c |
Data values expressed as mean ± SD (n = 6). Different superscripts (a–d) in each column indicate difference at the p < 0.01 level. For the Dunnet comparison of treatments with the control one-way analysis of variance (ANOVA) was followed at: *p < 0.05, #p < 0.01 and †p < 0.001.
Impact of FXE on the antioxidant enzymes of cardiac tissues in ratsa
| Treatment | CAT (U l−1) | POD (U l−1) | SOD (mg dl−1) | GST (mg dl−1) | GSR (mg dl−1) |
|---|---|---|---|---|---|
| Control | 5.54 ± 0.06a | 11.46 ± 0.12a | 4.56 ± 0.06a | 160.04 ± 5.14a | 205.39 ± 5.03a |
| DMSO + olive oil | 5.66 ± 0.04a | 11.29 ± 0.36a | 4.64 ± 0.04ab | 162.85 ± 5.17a | 200.55 ± 5.02a |
| CCl4 + olive oil | 1.3 ± 0.03†c | 6.44 ± 0.04†d | 1.36 ± 0.03†e | 90.23 ± 3.54†c | 123.75 ± 3.15†c |
| CCl4 + silymarin (100) | 5.49 ± 0.08a | 11.05 ± 0.04a | 3.66 ± 0.06bcd | 165.36 ± 2.44a | 183.69 ± 4.00†b |
| CCl4 + FXE (150) | 3.39 ± 0.06†b | 8.21 ± 0.08†c | 4.42 ± 0.09†cd | 148.01 ± 3.04†b | 185.45 ± 4.41†b |
| CCl4 + FXE (300) | 5.55 ± 0.16a | 11.09 ± 0.10a | 4.41 ± 0.05†d | 159.85 ± 4.64a | 199.72 ± 4.26a |
| FXE (150) | 5.46 ± 0.43a | 11.17 ± 0.56a | 4.53 ± 0.03abc | 164.02 ± 4.60a | 200.27 ± 5.87a |
| FXE (300) | 5.47 ± 0.05a | 11.28 ± 0.04b | 4.52 ± 0.05bcd | 161.64 ± 2.83a | 201.61 ± 3.21a |
Data values expressed as mean ± SD (n = 6). Different superscripts (a–d) in each column indicate difference at the p < 0.01 level. For the Dunnet comparison of treatments with the control one-way ANOVA was followed at: *p < 0.05, #p < 0.01 and †p < 0.001.
Impact of FXE on the biochemical parameters of cardiac tissues in ratsa
| Treatment | Protein | GSH (U l−1) | TBARS (U l−1) | H2O2 (mg dl−1) | DNA |
|---|---|---|---|---|---|
| Control | 3.02 ± 0.03a | 20.59 ± 1.22ab | 3.23 ± 0.05b | 1.19 ± 0.06d | 19.72 ± 0.16cde |
| DMSO + olive oil | 2.96 ± 0.09bc | 21.33 ± 0.46a | 3.34 ± 0.03b | 1.16 ± 0.03d | 19.29 ± 0.47e |
| CCl4 + olive oil | 1.02 ± 0.02†e | 10.09 ± 0.06†d | 6.69 ± 0.06†a | 2.6 ± 0.06†a | 49.26 ± 0.69†a |
| CCl4 + silymarin (100) | 3.03 ± 0.03a | 16.47 ± 0.38†c | 3.17 ± 0.07b | 1.16 ± 0.04d | 24.72 ± 0.05†b |
| CCl4 + FXE (150) | 2.81 ± 0.05†c | 19.4 ± 0.64#b | 3.30 ± 0.31b | 1.7 ± 0.03†b | 20.26 ± 0.31c |
| CCl4 + FXE (300) | 3.05 ± 0.03b | 20.35 ± 0.20ab | 3.28 ± 0.04b | 1.32 ± 0.02†c | 20.23 ± 0.18cd |
| FXE (150) | 3 ± 0.03bc | 21.23 ± 0.37a | 3.11 ± 0.06b | 1.22 ± 0.02d | 19.45 ± 0.32de |
| FXE (300) | 3.01 ± 0.19a | 20.81 ± 0.55a | 3.11 ± 0.40b | 1.18 ± 0.03d | 19.89 ± 0.16cde |
Data values expressed as mean ± SD (n = 6). Different superscripts (a–e) in each column indicate difference at the p < 0.01 level. For the Dunnet comparison of treatments with the control one-way ANOVA was followed at: *p < 0.05, #p < 0.01 and †p < 0.001.
Impact of FXE on the comet parameters of heart cells in ratsa
| Treatment | Comet length | Head length | Tail length | DNA head | DNA tail | Tail moment |
|---|---|---|---|---|---|---|
| Control | 29.28 ± 1.07b | 28.23 ± 0.77bc | 1.06 ± 1.36b | 97.73 ± 0.99a | 2.26 ± 0.99d | 0.52 ± 0.02c |
| DMSO + olive oil | 29.99 ± 0.72b | 27.27 ± 0.86c | 2.71 ± 1.00*b | 97.06 ± 0.95a | 2.94 ± 0.95d | 0.53 ± 0.00c |
| CCl4 + olive oil | 61.88 ± 1.16†a | 41.51 ± 1.91†a | 20.36 ± 1.76†a | 68.67 ± 1.14†d | 31.33 ± 1.14†a | 1.87 ± 0.06†a |
| CCl4 + silymarin (100) | 30.35 ± 0.56b | 29.18 ± 0.38bc | 1.17 ± 0.55b | 91.18 ± 1.11†b | 8.82 ± 1.11†c | 0.54 ± 0.02b |
| CCl4 + FXE (150) | 30.58 ± 0.78b | 29.94 ± 0.88*b | 0.63 ± 0.62b | 85.07 ± 0.84†c | 14.93 ± 0.84†b | 0.54 ± 0.02b |
| CCl4 + FXE (300) | 29.81 ± 0.76b | 28 ± 1.09bc | 1.81 ± 0.78b | 96.32 ± 0.60a | 3.67 ± 0.60d | 0.53 ± 0.01b |
| FXE (150) | 30.10 ± 0.67b | 28.72 ± 0.74bc | 1.38 ± 0.83b | 96.91 ± 0.76a | 3.08 ± 0.76d | 0.54 ± 0.01b |
| FXE (300) | 29.85 ± 0.73b | 28.85 ± 0.60bc | 1.00 ± 0.45b | 96.20 ± 0.56*a | 3.79 ± 0.56*d | 0.53 ± 0.01b |
Data values expressed as mean ± SD (n = 6). Different superscripts (a–d) in each column indicate difference at the p < 0.01 level. For the Dunnet comparison of treatments with the control one-way ANOVA was followed at: *p < 0.05, #p < 0.01 and †p < 0.001.
Fig. 3Comet analysis of the heart tissues in the presence of ethidium bromide stain (40×): (A) control; (B) vehicle treated (DMSO + olive oil); (C) CCl4 + olive oil treated; (D) CCl4 + silymarin (100 mg kg−1) treated; (E) CCl4 + FXE (150 mg kg−1) treated; (F) CCl4 + FXE (300 mg kg−1) treated; (G) FXE (150 mg kg−1) treated; and (H) FXE (300 mg kg−1) treated rats.
Fig. 4Histopathological studies of the heart. Hematoxylin and eosin stain (40×): (A) control; (B) vehicle treated (DMSO + olive oil) cardiac tissues; (C) CCl4 + olive oil; (D) CCl4 + silymarin (100 mg kg−1); (E) CCl4 + FXE (150 mg kg−1); (F) CCl4 + FXE (300 mg kg−1); (G) FXE (150 mg kg−1); and (H) FXE (300 mg kg−1).